CardioExchange Archive

March 10th, 2013

Was Atherosclerosis the Real Curse of the Mummy?

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. From a growing evidence base of mummies, researchers are now concluding that atherosclerosis may have been common in people […]

---

March 10th, 2013

Another Negative Trial of Darbepoetin Alfa

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. Once again a trial testing the erythropoiesis-stimulating agent darbepoetin alfa (Aranesp, Amgen) has produced a negative result. Results of […]

---

March 10th, 2013

Eplerenone May Help Prevent Heart Failure in Acute STEMI Patients

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. A new trial presented at the ACC in San Francisco suggests that the mineralocorticoid-receptor antagonist eplerenone (Pfizer, Inspra) may […]

---

March 10th, 2013

Fibrinolysis May Benefit Late-Arriving STEMI Patients

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. Although primary PCI has emerged as the best treatment for STEMI, most patients don’t receive this treatment within the […]

---

March 10th, 2013

Cangrelor During PCI May Reduce Ischemic Events

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. In the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial, the intravenous platelet […]

---

March 9th, 2013

HPS2-THRIVE: A ‘Disappointing But Clear’ Result

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. The results of HPS2-THRIVE were “disappointing but clear,”  said Jane Armitage, who presented the results this morning at the ACC […]

---

March 9th, 2013

Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. The already complicated story behind the PREVAIL trial, which was designed to confirm the safety and efficacy of the […]

---

March 7th, 2013

Hospitals Are Seeing Rapidly Growing Numbers of Adults with Congenital Heart Disease

Larry Husten, PHD

Hospitals are treating increasing numbers of adults with congenital heart disease, thanks to tremendous progress in treatment for this condition in recent decades. A clear picture of this dramatic change emerges in a new study, presented at the ACC in San Francisco and published simultaneously in JAMA. Jared O’Leary and colleagues analyzed data from the Nationwide […]

---

March 5th, 2013

FDA Again Rejects ACS Indication for Rivaroxaban

Larry Husten, PHD

For the second time the FDA has turned down the supplemental new drug application (sNDA) for the proposed indication of rivaroxaban (Xarelto, Johnson & Johnson) to treat patients with acute coronary syndrome (ACS). Despite early hopes, the ACS indication has proved tantalizingly elusive for the drug.  When the pivotal ATLAS ACS 2-TIMI 51 trial was unveiled in 2011 it […]

---

March 4th, 2013

Veterans Study Finds HIV to Be an Independent Risk Factor for MI

Larry Husten, PHD

Although it has long been suspected that people with the HIV virus are at increased risk for cardiovascular (CV) disease, reliable data has not been available. Now a new study published online in JAMA Internal Medicine provides a much clearer picture of the relationship between CV disease and HIV. Matthew Freiberg and colleagues analyzed data from 82,459 HIV-positive and matched […]

---